^
    Back
    Association details:
    Biomarker:KRAS G13D
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancer Discov
    Title:

    Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations

    Excerpt:
    Sequence analysis of VACO-RE and VACO-RM cells revealed that each resistant variant retained the original BRAF V600E mutation, but that each acquired a distinct exon 2 mutation in KRAS (G12D and G13D, respectively) that was not present in the parental cell line, with no change in KRAS copy number (Figs. 1B, S1).
    DOI:
    10.1158/2159-8290.CD-14-1518